Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma

Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma BLOOD ADVANCES Tandon, N., Sidana, S., Rajkumar, S., Gertz, M. A., Buadi, F. K., Lacy, M. Q., Kapoor, P., Gonsalves, W., Dispenzieri, A., Kourelis, T., Warsame, R., Dingli, D., Fonder, A. L., Hayman, S. R., Hobbs, M. A., Hwa, Y., Kyle, R. A., Leung, N., Go, R. S., Lust, J. A., Russell, S. J., Kumar, S. K. 2019; 3 (5): 744–50

Abstract

We evaluated the impact of achieving a rapid response in 840 newly diagnosed multiple myeloma patients from 2004 to 2015. Rates of very good partial response (VGPR) or better were 29% (240/840) after 2 cycles of treatment, 42% (350/840) after 4 cycles of treatment, and 66% (552/840) as best response. Early responders after 2 cycles of treatment had higher rates of light chain disease, anemia, renal failure, International Staging System (ISS) stage III disease, and high-risk cytogenetics, especially t(4;14), and were more likely to have received triplet therapy and undergo transplant. Median progression-free survival (PFS) and overall survival (OS) were not different among patients with =VGPR and

View details for DOI 10.1182/bloodadvances.2018022806

View details for Web of Science ID 000460943400007

View details for PubMedID 30824418

View details for PubMedCentralID PMC6418495